Global Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory), And By Geography - Forecasts From 2022 To 2027

The global flu diagnostic and treatment market was valued at US$ 43,009.02 million for the year 2020, growing at a CAGR of 13.45% to reach a market size of US$ 1,04,024.09 million by 2027. The global flu diagnostic and treatment market is poised to surge at a notable rate throughout the forecast period, majorly on account of the high prevalence of flu throughout the globe. The rising investments in R&D by key market players in the expansion of product lines and especially for improving the quality of products for the betterment of health is also expected to propel the growth opportunities for the market to surge during the forecast period and beyond.

In addition, the rising geriatric population throughout the globe, especially in countries like Japan, Italy, and Germany, among others, along with the presence of well-established healthcare systems in these countries, is also bolstering the flu diagnostic and treatment market growth during the next five years. Older people need more care and better health facilities as they are more prone to flu due to a weak immune system. The need for quality flu diagnosis and treatment is greater for the elderly; this has further increased the demand for flu diagnostic and treatment kits. According to the World Bank data, the population aged 65 and above of the total population has increased from 7.49% of the total population in the world in the year 2009 to 8.87% of the total world population in the year 2018. Influenza is considered a communicable and highly contagious disease. However, the disease is characterized by a sudden onset of sore throat, muscle and joint pain, dry cough, and fever. However, recovery without intensive medical attention is possible, but, in some cases, this may lead to severe illness and sometimes leads to death, especially in the high-risk population, which primarily includes pregnant women, aged people, infants, and people with immunosuppressive conditions.

Growth Factors:

• The rising prevalence of influenza across the globe is significantly driving the market growth

The high prevalence of influenza around the globe, coupled with the rising prevalence of influenza in numerous countries due to the non-availability of proper healthcare services and facilities, is one of the prime factors driving the market growth for the coming five years. According to the U.S. Department of Health and Human Services, the number of cases of influenza-like illness increased remarkably from the 2011-2012 season to the 2017-2018 season. The number of influenza-like illness cases reached around 45,000,000 by the 2017-2018 season from 9,30,000 in the 2011-2012 season. Furthermore, according to the World Health Organisation (WHO), North America saw a rise in influenza activity with the majority of people infected with influenza A viruses, with at least 80% of adult influenza-associated hospitalizations being associated with influenza A viruses. The rise in influenza cases around the world is increasing the use of flu diagnostics and treatment to improve the health of people.

The growing prevalence of flu in many countries across the European and Asia Pacific region is also propelling the market growth during the next five years.

• Type A flu to rule the market

On the basis of the type of flu, the global flu diagnostic and treatment market has been classified into Type A and Type B viruses. The flu diagnostic and treatment market for type A virus is anticipated to hold a major market share throughout the forecast period as type A viruses are the most common flu virus that is diagnosed in many countries across the world. Similarly, the number of clinically diagnosed cases along with the number of hospitalizations with type A flu is also considerably higher than the type B segment. For instance, according to the report from the European Center for Disease Prevention and Control, during the last weeks of the 2018-2019 flu season, there were a total of 16,472 positive sentinel specimens tested. Out of these, around 99% were tested for Type A and only 1% were Type B.

The type B flu segment is projected to hold a low share of the market as its incidence is comparatively lower than type A flu. However, the incidence of type B flu is growing, especially throughout the APAC region, which is considered one of the prime factors bolstering the growth of this segment over the forecast period.

• Outpatient clinics are expected to show notable growth during the next five years

On the basis of end-user, the global flu diagnostic and treatment market has been classified into hospital laboratories, outpatient clinics, and reference laboratories. The outpatient clinics segment is anticipated to show decent growth during the next five years as these healthcare settings offer point-of-care treatments at comparatively low costs. The hospital laboratory segment is projected to hold a significant share in the global flu diagnostic and treatment market during the next five years as hospitals offer long-term care facilities and are considered more reliable than other end-users.

Asia Pacific region to show robust growth

The flu diagnostic and treatment market has been divided into five regions: North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The Asia Pacific region is anticipated to show robust growth throughout the forecast period owing to the fact that there is an increasing prevalence of influenza in major countries of the region, such as India, China, and Indonesia, among others, coupled with rising healthcare expenditure, especially in the developing countries. The North American region is projected to hold a noteworthy market share on account of the availability of a well-established healthcare sector in countries like the U.S and Canada along with high healthcare spending. All these factors together support the noteworthy share of North America in the global flu diagnostic and treatment market throughout the forecast period.

Recent development and expansions

• On June 30, 2022, BD (Becton, Dickinson, and Company), a global medical technology company, introduced the BD MAXTM Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for Influenza A + B, SARS-CoV-2and Respiratory Syncytial Virus (RSV).
• On December 6, 2021, Roche will launch the SARS-CoV-2 and Flu A/B Rapid Antigen Test in countries that accept the CE Mark to enable rapid differentiation of viral respiratory infections.
• Quidel receives a CE mark for COVID-19, flu, and RSV diagnostic test on July 13, 2021.

COVID-19 impact on the Flu Diagnostic And Treatment Market

Both influenza and COVID-19 viruses cause respiratory problems. Furthermore, both are spread through contact, droplets, and fomites. COVID-19 patients are misdiagnosed with influenza in the initial phase.  However, it was quickly discovered that factors such as immunity, age group, transmission rate, vaccination, and a few others differ significantly between COVID-19 and influenza. As a result of recognizing the distinction between these two infections, the demand for influenza kits has returned to normal, and the importance of a comprehensive approach to diagnosis and treatment has grown in order to tackle COVID-19.

Global Flu Diagnostic and Treatment Market Scope:

Market Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Other
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Indonesia
    • Taiwan
    • Others

Frequently Asked Questions (FAQs)

Q1. What is the size of the global flu diagnostic and treatment market?
A1. Flu Diagnostic And Treatment Market was valued at US$43,009.02 million in 2020.

Q2. What are the growth prospects for the flu diagnostic and treatment market?
A2. The flu diagnostic and treatment market is projected to grow at a CAGR of 13.45% during the forecast.

Q3. What will be the global flu diagnostic and treatment market size by 2027?
A3. The global flu diagnostic and treatment market is projected to reach a total market size of US$1,04,024.09 million in 2027. 

Q4. Which region holds the largest share of the flu diagnostic and treatment market?
A4. The Asia Pacific region is anticipated to show robust growth throughout the forecast period owing to the fact that there is an increasing prevalence of influenza in major countries of the region.

Q5. What factors are anticipated to drive the global flu diagnostic and treatment market growth?
A5. The rising prevalence of influenza across the globe is significantly driving the flu diagnostic and treatment market growth.

Quidel Corporation

F. Hoffmann-La Roche Ltd

BD

Thermo Fisher Scientific Inc.

3M

SA Scientific

Sekisui Diagnostics

Meridian Bioscience™

Oxford Biosystems

Pfizer

Bayer AG

GlaxoSmithKline plc